<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432023000100240</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v6i16.222</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diagnóstico y tratamiento clínico del síndrome antifosfolipídico seronegativo]]></article-title>
<article-title xml:lang="en"><![CDATA[Diagnostic and clinical treatment of seronegative antiphospholipid syndrome]]></article-title>
<article-title xml:lang="pt"><![CDATA[Diagnóstico e tratamento clínico da síndrome antifosfolípide soronegativa]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Eguiguren]]></surname>
<given-names><![CDATA[Loretto Charmaine Mata]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Clavijo]]></surname>
<given-names><![CDATA[Christian Gabriel Villa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[Cuenca ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2023</year>
</pub-date>
<volume>6</volume>
<numero>16</numero>
<fpage>240</fpage>
<lpage>250</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432023000100240&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432023000100240&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432023000100240&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El Síndrome antifosfolipídico (SAF) se describió por primera vez en el año de 1982 por el científico Graham R. V Hughes. En el año 2003 Hughes y Khamasht lograron identificar una variable poco común de SAF denominada seronegativa, la cual se manifiesta con el cuadro trombolítico característico de esta enfermedad sin embargo existe ausencia de positividad en las pruebas serológicas, debido a que es una patología de difícil identificación y diagnóstico requiere de especial atención puesto que puede conllevar a múltiples complicaciones al no ser tratada de manera oportuna. Objetivo. Describir el diagnóstico y tratamiento del Síndrome Antifosfolipídico Seronegativo. Metodología. Se realizó una revisión sistemática donde se incluyeron estudios originales, metaanálisis y experimentales con fecha de publicación de los últimos 5 años en idioma inglés y español. Se utilizaron bases de datos virtuales como Pubmed, Scielo y Google Scholar. Conclusión. El Síndrome antifosfolipídico seronegativo una patología de difícil reconocimiento debido a la negatividad que refleja en las pruebas serológicas, para el diagnóstico inicialmente se debe tomar en cuenta las manifestaciones clínicas del paciente para obtener una sospecha, posterior a ello, es importante la realización de pruebas serológicas en donde primero se realice la detección de anticuerpos que forman parte de los criterios de SAF.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Antiphospholipid syndrome (APS) was first described in 1982 by the scientist Graham R. V Hughes. In 2003 Hughes and Khamasht managed to identify an uncommon variable of FAS called seronegative, which manifests with the characteristic thrombolytic picture of this disease however there is absence of positivity in serological tests, because it is a pathology of difficult identification and diagnosis requires special attention since it can lead to multiple complications if not treated in a timely manner. Objective. To describe the diagnosis and treatment of Seronegative Antiphospholipid Syndrome. Methodology. A systematic review was carried out including original studies, meta-analysis and experimental studies published in the last 5 years in English and Spanish. Virtual databases such as Pubmed, Scielo and Google Scholar were used. Conclusion. Seronegative antiphospholipid syndrome is a pathology that is difficult to recognize due to the negativity reflected in serological tests. For diagnosis, the clinical manifestations of the patient should be taken into account initially to obtain a suspicion, after which it is important to carry out serological tests in which the detection of antibodies that are part of the criteria for FAS should be performed first.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO A síndrome antifosfolipídica (SAF) foi descrita pela primeira vez em 1982 pelo cientista Graham R. V Hughes. Em 2003, Hughes e Khamasht conseguiram identificar uma variável rara da SAF denominada soronegativa, que se manifesta com o quadro trombolítico característico dessa doença, porém há ausência de positividade nos testes sorológicos, pois se trata de uma patologia de difícil identificação e o diagnóstico requer atenção especial, uma vez que pode levar a múltiplas complicações se não for tratada em tempo hábil. Objetivo. Descrever o diagnóstico e o tratamento da Síndrome do Anticorpo Antifosfolípide Soronegativo. Metodologia. Foi realizada uma revisão sistemática incluindo estudos originais, meta-análises e estudos experimentais publicados nos últimos 5 anos em inglês e espanhol. Foram utilizados bancos de dados virtuais como Pubmed, Scielo e Google Scholar. Conclusão. A síndrome antifosfolípide soronegativa é uma patologia de difícil reconhecimento devido à negatividade refletida nos testes sorológicos. Para o diagnóstico, inicialmente devem ser levadas em conta as manifestações clínicas do paciente para obter uma suspeita e, em seguida, é importante realizar testes sorológicos nos quais se realiza primeiro a detecção de anticorpos que fazem parte dos critérios da SAF.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome Antifosfolipídico]]></kwd>
<kwd lng="es"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="es"><![CDATA[Terapéutica]]></kwd>
<kwd lng="en"><![CDATA[Antiphospholipid Síndrome]]></kwd>
<kwd lng="en"><![CDATA[Diagnosis]]></kwd>
<kwd lng="en"><![CDATA[Therapeutics]]></kwd>
<kwd lng="pt"><![CDATA[Síndrome Antifosfolípide]]></kwd>
<kwd lng="pt"><![CDATA[Diagnóstico]]></kwd>
<kwd lng="pt"><![CDATA[Terapêutica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashorobi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ameer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombosis]]></article-title>
<source><![CDATA[StatPearls]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Treasure Island (FL) ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walter]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Klein Haneveld]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lely]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Bloemenkamp]]></surname>
<given-names><![CDATA[KWM]]></given-names>
</name>
<name>
<surname><![CDATA[Limper]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kooiman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy outcome predictors in antiphospholipid syndrome: A systematic review and meta-analysis.]]></article-title>
<source><![CDATA[Autoimmun Rev.]]></source>
<year>2021</year>
<volume>20</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petri]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiphospholipid syndrome]]></article-title>
<source><![CDATA[Transl Res]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Hasbani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Taher]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Sciascia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Uthman]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiphospholipid syndrome: the need for new international classification criteria.]]></article-title>
<source><![CDATA[Expert Rev Clin Immunol]]></source>
<year>2021</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>385-94</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sayar]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Moll]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Isenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management.]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2021</year>
<page-range>213-21</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da Rosa]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa-Pinto]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Barilaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bettencourt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study.]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2022</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyamae]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kawabe]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome]]></article-title>
<source><![CDATA[Journal of Clinical Medicine (Internet)]]></source>
<year>2021</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Funke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticuerpos antifosfolípidos sin criterio: una revisión narrativa]]></article-title>
<source><![CDATA[Scielo(Internet)]]></source>
<year>2020</year>
<volume>66</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yazici]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definición y enfoque de tratamiento de las manifestaciones clínicas no de criterio del síndrome antifosfolípido.]]></article-title>
<source><![CDATA[Pubmed (Internet)]]></source>
<year>2020</year>
<volume>7</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>180-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Litvinova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Darnige]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kirilovsky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burnel]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[de Luna]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dragon]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria. Frontiers in immunology(Internet)]]></source>
<year>2018</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-71</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome]]></article-title>
<source><![CDATA[Pubmed]]></source>
<year>2019</year>
<page-range>205-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincenzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seronegative autoimmune diseases: A challenging diagnosis.]]></article-title>
<source><![CDATA[Pubmed]]></source>
<year>2022</year>
<volume>21</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>103-43</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["Non-criteria" antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort.]]></article-title>
<source><![CDATA[Pubmed]]></source>
<year>2020</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misasi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Longo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Recalchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Caissutti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Riitano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Manganelli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Garofalo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sorice]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Capozzi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS"]]></article-title>
<source><![CDATA[Int J Mol Sci.]]></source>
<year>2020</year>
<volume>21</volume>
<numero>21</numero>
<issue>21</issue>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enescu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Basida]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zalavadiya]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Akram]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sarakbi]]></surname>
<given-names><![CDATA[H. A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic Dilemma: Catastrophic or Seronegative Antiphospholipid Syndrome]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2021</year>
<volume>13</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>187-245</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pastori]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Misasi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sorice]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cribari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Menichelli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Violi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pignatelli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: ¿Need for New Diagnostic Criteria?]]></article-title>
<source><![CDATA[Eur J Case Rep Intern Med.]]></source>
<year>2019</year>
<volume>6</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pignatelli]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management]]></article-title>
<source><![CDATA[Haematologica]]></source>
<year>2020</year>
<volume>105</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>562-72</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da Rosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Barilaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bettencourt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study]]></article-title>
<source><![CDATA[Arthritis research &amp; therapy]]></source>
<year>2022</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alijotas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry]]></article-title>
<source><![CDATA[Pubmed]]></source>
<year>2020</year>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1306-14</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abisror]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study]]></article-title>
<source><![CDATA[Pubmed]]></source>
<year>2020</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fredi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies.]]></article-title>
<source><![CDATA[Pubmed]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghembaza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saadoun]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Antiphospholipid Syndrome.]]></article-title>
<source><![CDATA[Biomedicines]]></source>
<year>2020</year>
<volume>8</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abisror]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Marozio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Esteve Valverde]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Udry]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pleguezuelo]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Billoir]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer-Pickel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Urbanski]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zigon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[De Moreuil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hoxha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bezanahary]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Carbillon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kayem]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bornes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yelnik]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Johanet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nicaise-Roland]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salle]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Latino]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hachulla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Benedetto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bourrienne]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Benhamou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Alijotas-Reig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fain]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Mekinian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Forum on Antiphospholipid Antibodies. Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study]]></article-title>
<source><![CDATA[RMD Open]]></source>
<year>2020</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein Haneveld]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lemmen]]></surname>
<given-names><![CDATA[CHC]]></given-names>
</name>
<name>
<surname><![CDATA[Brunekreef]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Bijl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jansen]]></surname>
<given-names><![CDATA[AJG]]></given-names>
</name>
<name>
<surname><![CDATA[de Leeuw]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Spierings]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Limper]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ARCH Study Group. Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands.]]></article-title>
<source><![CDATA[Rheumatol Adv Pract]]></source>
<year>2020</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
